PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9900430-1
1108.

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/40, 15/86, A61K 39/12, 39/295

A2

(11) International Publication Number: WO 98/13500

(43) International Publication Date: 2 April 1998 (02.04.98)

(21) International Application Number: PCT/EP97/05214

(22) International Filing Date: 23 September 1997 (23.09.97)

(30) Priority Data:
1035/96 24 September 1996 (24.09.96) DK

(71) Applicants *(for all designated States except US)*: BAVARIAN NORDIC RESEARCH INSTITUTE A/S [DK/DK]; Naverland 2, DK–2600 Glostrup (DK). UNIVERSITY MALAYSIA SARAWAK [MY/MY]; 94300 Kota Samarahan, Sarawak (MY). GSF – FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT GMBH [DE/DE]; Ingolstädter Landstrasse 1, D–85764 Neuherberg (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CARDOSA, Mary, Jane [MY/MY]; 96 Jalan Wan Abdul Rahman, Lorong 4, 93300 Kuching, Sarawak (MY). SUTTER, Gerd [DE/DE]; Germaniastrasse 15, D–80802 München (DE). ERFLE, Volker [DE/DE]; La Place Strasse 4, D–81679 München (DE).

(74) Agent: GRÜNECKER, KINKELDEY, STOCKMAIR & SCHWANHÄUSSER; Maximilianstrasse 58, D–80538 München (DE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS ANTIGENS, AND THE USE THEREOF IN VACCINES

(57) Abstract

Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.